Search results for "Oncologia"

showing 10 items of 386 documents

Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?

2015

Introduction: Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC). Alternative first- and second-line treatments are a significant unmet medical need, and several biologic agents have been tested in recent years, with poor results. Therefore, angiogenic pathways and the cytokine cascade remain possible targets in HCC. Recent studies suggest a role of epigenetic processes, associated with the initiation and development of HCC. In this field, DNA methylation, micro-RNAs (miRNAs) and tumor microenvironment cells became a possible new target for HCC treatment. Areas covered: This review explains the possible role of DNA methylation and histone deacetylase inhibito…

Settore MED/06 - Oncologia MedicaClinical BiochemistrytivantinibEpigenesis GeneticAntineoplastic Agentchemistry.chemical_compoundHistone Deacetylase InhibitorDrug DiscoveryTumor MicroenvironmentMolecular Targeted TherapyplateletmicroRNALiver Neoplasmshepatocellular carcinomaSorafenibVEGFLiver NeoplasmHepatocellular carcinomaDNA methylationMolecular MedicineepigeneticHumanmedicine.drugPhenylurea CompoundSorafenibNiacinamideCarcinoma HepatocellularAntineoplastic AgentsBiologymicroRNAmedicineAnimalsHumansEpigeneticsTivantinibPharmacologyTumor microenvironmentAnimalDrug Discovery3003 Pharmaceutical SciencePhenylurea CompoundsDNA Methylationmedicine.diseasedigestive system diseasesHistone Deacetylase InhibitorsMicroRNAschemistryDrug DesignImmunologyCancer researchHistone deacetylaseExpert opinion on therapeutic targets
researchProduct

Diagnostic, Prognostic and Therapeutic Value of Gene Signatures

2012

Gene expression studies have revealed diagnostic profiles and upregulation of specific pathways in many solid tumors. Some gene-expression signatures are already used as predictors of relapse in early breast cancer patients. The explosion of new information in gene expression profiling could potentially lead to the development of tailored treatments in many solid tumors. In addition, many studies are ongoing to validate these signatures also in predicting response to hormonal, chemotherapeutic, and targeted agents in breast cancer as well as in other tumors. This book has been carried out with the aim of providing readers a useful and comprehensive resource about the range of applications o…

Settore MED/06 - Oncologia MedicaDiagnostic Value Prognostic Value Therapeutic Value Gene Signatures
researchProduct

GENE SIGNATURE IN GIST

2011

Settore MED/06 - Oncologia MedicaGENEGIST
researchProduct

I tumori stromali gastrointestinali: dalla biologia alla clinica

2014

Settore MED/06 - Oncologia MedicaGIST imatinib sunitinib
researchProduct

Targeted Therapies in Gastrointestinal Stromal Tumors

2015

Not available

Settore MED/06 - Oncologia MedicaGIST target therapy
researchProduct

HIF-1a induces downregulated expression of Aurora A in breast cancer cell lines

2012

Background: Aurora A (AURKA) is an oncogenic serine/treonine kinase that play a critical role during mitosis, governing the correct distribution of genetic material to the daughter cells. AURKA is overexpressed in many types of human tumors including breast cancer and its deregulated expression, inducing alteration of mitotic spindle, chromosomal segregation and aneuploidy can lead to malignant transformation of cells. Aims: Since hypoxia is a typical tumoral condition which influences the expression of various proteins involved in proliferation and cell cycle progression, aim of our study was to obtain new insights into AURKA regulation in breast cancer cell lines cultured under normoxic a…

Settore MED/06 - Oncologia MedicaHIF-1aAurora Acancer cell line
researchProduct

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

2022

Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immune-checkpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-…

Settore MED/06 - Oncologia MedicaHematologyMMR deficiencyColorectal cancerMMRPD-1/PD-L1DNA Mismatch RepairTumor-agnostic therapyOncologyNeoplasmsSolid tumorsHumansMicrosatellite InstabilityImmunotherapyColorectal NeoplasmsMSI
researchProduct

The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-an…

2016

Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of liver metastasis (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Materials and Methods: Data from all published studies reporting survival outcomes (RFS and/or OS) of CRC patients who received resection of CLM, stratified by KRAS and/or BRAF mutation status were collected by sear…

Settore MED/06 - Oncologia MedicaKRAS BRAF prognostic colorectal cancer liver metastasis meta-analysis
researchProduct

EXPRESSION OF METIOLLOPROTEINASES ( MMP2-MMP9 ) AND CYCLOOXIGENASES ( COX1-COX2 ) IN SALIVARY GLAND TUMORS

2011

Background Salivary neoplasms of the major salivary glands are uncommon: the annual incidence rates in the world vary between greater than 0.05 and less than 2 per 100,000. Most salivary gland tumours are benign and they represent an histological heterogeneous group with the greatest diversity of morphological and cellular features, in fact, these tumours are characterized by an extremely varied histomorphological phenotype due to combinations of different epitheliomorphic and mesenchymomorphic features. The histogenesis is uncertain but the bicellular theory of origin has been accepted and states that malignant transformation of reserve cell from either the intercalated or excretory duct a…

Settore MED/06 - Oncologia MedicaMETIOLLOPROTEINASESSALIVARY GLANDCYCLOOXIGENASESTUMORS
researchProduct

UNRAVELLING THE ROLES OF THE NUCLEAR PROTEIN 1 DURING ER-STRESS INDUCTION

2020

Background: NUPR1 was described as a transcriptional factor involved in the regulation of various cellular stress-response genes, playing a crucial role in the condition of the endoplasmic-reticulum (ER) stress, thus emerging as a common molecular factor of different pathologies, obesity, hepatic steatosis, and cancer. In the present work we aim to explore how NUPR1 interacts with some pivotal genes that are the major modulators of the ER stress and metabolic cell functions. In particular we investigated the biochemical and molecular effects arising from the loss of NUPR1 in ER stress physiological conditions. Methods: We used prolonged high fat diet (HFD) feeding to induce ER stress physio…

Settore MED/06 - Oncologia MedicaNuclear protein 1 P8 NUPR1 ER stress ATF6 PERK EIF2alfa cancer obesity hepatic steatosis mouse model metabolism geneSettore BIO/11 - Biologia Molecolare
researchProduct